News in immunology

Česká verzia

Authors: Jiřina Bartůňková; Markéta Bloomfield; Magdalena Havlišová; Adam Klocperk; Helena Kubešová; Michal Podrazil; Zuzana Střížová; Anna Šedivá
Authors place of work: Ústav imunologie 2. LF UK a FN v Motole, Praha
Published in the journal: Vnitř Lék 2023; 69(2): 133-137
Category: News in...
doi: https://doi.org/10.36290/vnl.2023.021

Summary

The field of immunology has undergone a very significant development in recent decades, which has been reflected especially in the beginning of this millennium in significant advances in the understanding of the immune system and in the application of this knowledge in practice. The progress and acceleration of research and advances in the field of immunology was further prompt by the unexpected onset of the COVID-19 pandemic in 2020. The intense scientific work has not only led to the development of our understanding of the immune response to viruses, but also to the rapid conversion of this knowledge into practical pandemic management on a global scale, as exemplified by the development of vaccines against SARS-Cov-2 virus. The pandemic era has further contributed to the acceleration of the application of not only biological discoveries but also technological approaches into practical applications, such as use of advanced mathematics, computer science and, more recently, artificial intelligence which are all are adding to the advances that are significantly moving the field of immunology forward.

In this communication, we present specific advances in particular areas of immunopathology, which are mainly allergy, immunodeficiency, immunity and infection, vaccination, autoimmune diseases and cancer immunology.

Keywords:

allergy – vaccination – Immunity – cancer – immunodeficiency – autoimmune disease – infection

Zdroje

1. Calhoun WJ. The new era of add‑on asthma treatments: where do we stand? Allergy Asthma Clin Immunol. 2022;18(1):42.

2. Atanasio A. Biologics as novel therapeutics for the treatment of allergy: Challenges and opportunities. Front Allergy. 2022;3:1019255.

3. Global Initiative for Asthma Global strategy for asthma management and prevention. Updated 2022. www.ginasthma.org.

4. Tangye SG, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J. Clin. Immunol. (2022) doi:10.1007/s10875-022-01289-3.

5. Blom M, et al. Second Tier Testing to Reduce the Number of Non‑actionable Secondary Findings and False‑Positive Referrals in Newborn Screening for Severe Combined Immunodeficiency. J. Clin. Immunol. 41, 1762–1773 (2021).

6. McInnes IB, Gravallese EM.Immune‑mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol. 2021;21(10):680-686.

7. Powers AC. Type 1 diabetes mellitus: much progress, many opportunities. J Clin Invest. 2021;131(8):e142242.

8. Misztal MC, Liao F, Couse M, et al. Genome‑Wide Sequencing Identified Rare Genetic Variants for Childhood‑Onset Monogenic Lupus. J Rheumatol. 2022 Nov 15:jrheum.220513.

9. Bastard, et al. „Autoantibodies against type I IFNs in patients with life‑threatening COVID- 19.“ Science. Sept 2020. doi: 10.1126/science.abd4585.

10. Zhang T, et al. Inborn errors of type I IFN immunity in patients with life‑threatening COVID-19. Science. Sept 2020. doi: 10.1126/science.abd4570.

11. Netea M, et al. Defining trained immunity and its role in health and disease“. Nature Reviews. Immunology. 2020(6):375-388. doi:10.1038/s41577-020-0285-6.

12. Piret J, Boivin G. Viral Interference between Respiratory Viruses. Emerg Infect, DiS. Feb 2022;28(2):273-281. doi: 10.3201/eid2802.211727.

13. Maruggi G, Zhang C, Li J, Ulmer J B, Yu D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019;27(4):757-772. doi: 10.1016/j.ymthe.2019. 01. 020.

14. Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine. 2021;39(16):2190-2200. doi: 10.1016/j.vaccine. 2021. 03. 038.

15. Steinle H, Behring A, Schlensak C, Wendel H P, Avci‑Adali M. Concise review: application of in vitro transcribed messenger RNA for cellular engineering and reprogramming: progress and challenges. Stem Cells. 2017;35(1):68-79. doi: 10.1002/stem.2402.

16. Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19(1):37-50. doi:10.1038/s41571-021-00552-7.

17. Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody‑Drug Conjugates: A Comprehensive Review. Mol Cancer Res. 2020;18(1):3-19. doi:10.1158/1541-7786.MCR-19-0582

18. Michielin O, Lalani AK, Robert C, Sharma P, Peters S. Defining unique clinical hallmarks for immune checkpoint inhibitor‑based therapies [published correction appears in J Immunother Cancer. 2022;10(12):]. J Immunother Cancer. 2022;10(1):e003024. doi:10.1136/ jitc-2021-003024.